cardiovascular benefits of glp 1 agonists GLP-1 receptor and outcome trials: An update GLP-1 Receptor Agonists for the

Red flag symptoms requiring urgent assessment: Severe, persistent vomiting Inability to tolerate oral intake for more than 24 hours, suggesting possible gastroparesis or other complications Signs of dehydration Decreased urine output, dizziness, dry mucous membranes, or tachycardia Severe abdominal pain Particularly if acute, localized, or associated with fever, which may indicate pancreatitis or other acute abdominal pathology Right upper quadrant pain, fever, or jaundice Suggesting possible gallbladder disease Severe abdominal distension with inability to pass stool or gas Potential bowel obstruction or ileus Hematemesis or melena Suggesting gastrointestinal bleeding Progressive dysphagia Difficulty swallowing that worsens over time Situations requiring routine consultation: Patients should contact their healthcare provider for non-urgent evaluation when experiencing persistent nausea or vomiting lasting beyond 2-3 weeks at a stable dose, as this may indicate inadequate adaptation or the need for dose adjustment

The next wave dual and triple agonists (GLP-1 + GIP + glucagon: tirzepatide, retatrutide, survodutide) are showing superior fat loss, better hepatic outcomes, and potentially preserved lean mass

Strength training and eating a high-protein diet can combat muscle loss if youre losing weight using traditional methods in those instances, a person can expect the weight they lose to be about 25% lean mass and 75% fat mass

Adding liraglutide to insulin therapy has also been seen to have significant reductions in HbA1c and weight loss, a 0.8% reduction of HbA1c and a mean weight loss of 5.1 kg, respectively

That, combined with possible nutritional deficiencies from eating less, could lead to shedding

Laboratory data were also obtained from ABUCASIS